Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
46 hedge funds and large institutions have $206M invested in Cidara Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
15% more funds holding
Funds holding: 40 → 46 (+6)
12% more capital invested
Capital invested by funds: $184M → $206M (+$22.3M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10.2% less ownership
Funds ownership: 97.5% → 87.3% (-10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.8M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$11.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.66M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.49M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$3.74M |
| 2 |
CC
Checkpoint Capital
San Francisco,
California
|
-$2.06M |
| 3 |
SC
Stempoint Capital
New York
|
-$1.28M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$632K |
| 5 |
Citigroup
New York
|
-$156K |
CDTX Hedge Fund Activity: Q1 2025 in Review
46 of the 7,469 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2025, worth a combined $206M — up 12% from $184M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CDTX positions and 2 closed out — a net gain of 6 holders — while 19 added to existing stakes and 9 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $13.8M. The largest seller was BVF Inc, cutting an estimated $3.74M.
- 46 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2025, up from 40 in Q4 2024.
- Funds reported $206M of Cidara Therapeutics stock for Q1 2025, up 12% quarter-over-quarter.
- 8 funds opened new Cidara Therapeutics positions in Q1 2025 and 2 closed out, a net change of +6 holders.
- The largest Cidara Therapeutics buyer in Q1 2025 was Adage Capital Partners, an estimated $13.8M added.
- The largest Cidara Therapeutics seller in Q1 2025 was BVF Inc, an estimated $3.74M sold.
Based on aggregated 13F filings for Q1 2025.